Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab-Reference-Cited by-同舟云学术

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Published:2017-02 Issue:2 Volume:28 Page:368-376
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Menzies A.M.,Johnson D.B.,Ramanujam S.,Atkinson V.G.,Wong A.N.M.,Park J.J.,McQuade J.L.,Shoushtari A.N.,Tsai K.K.,Eroglu Z.,Klein O.,Hassel J.C.,Sosman J.A.,Guminski A.,Sullivan R.J.,Ribas A.,Carlino M.S.,Davies M.A.,Sandhu S.K.,Long G.V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/2/368/11203620/mdw443.pdf

Reference22 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 671 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response;Pharmacology & Therapeutics;2024-10

3. Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy;Biomedicines;2024-09-12

4. Immuncheckpointinhibitoren bei Autoimmunerkrankungen;Im Fokus Onkologie;2024-09

5. Peripheral nervous system immune-related adverse events due to checkpoint inhibition;Nature Reviews Neurology;2024-08-09